TYRA-300
- Generic Name
- TYRA-300
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
Phase 1
Recruiting
- Conditions
- Urothelial CarcinomaSolid Tumor, AdultNon-muscle-invasive Bladder CancerAdvanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaAdvanced Solid TumorSolid TumorUrinary Tract CancerUrinary Tract Tumor
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Tyra Biosciences, Inc
- Target Recruit Count
- 310
- Registration Number
- NCT05544552
- Locations
- 🇺🇸
Cleveland Clinic - Main Campus, Cleveland, Ohio, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath